Literature DB >> 14659122

Ductal carcinoma in situ: USC/Van Nuys Prognostic Index and the impact of margin status.

Melvin J Silverstein1, Claire Buchanan.   

Abstract

As our knowledge of ductal carcinoma in situ (DCIS) continues to evolve, treatment decision-making has become increasingly complex and controversial for both patients and physicians. Treatment options include mastectomy, and breast conservation with or without radiation therapy. Data produced from the randomized clinical trials for DCIS has provided the basis for important treatment recommendations, but are not without limitations. In this article, we review our prospectively collected database consisting of 1036 patients with DCIS treated at the Van Nuys Breast Center and the USC/Norris Comprehensive Cancer Center. We review the use of the USC/Van Nuys Prognostic Index, a clinical algorithm designed to assist physicians in selection of appropriate treatments, and examine the impact of margin status as a sole predictor of local recurrence.

Entities:  

Mesh:

Year:  2003        PMID: 14659122     DOI: 10.1016/s0960-9776(03)00153-x

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  12 in total

Review 1.  Network meta-analysis of margin threshold for women with ductal carcinoma in situ.

Authors:  Shi-Yi Wang; Haitao Chu; Tatyana Shamliyan; Hawre Jalal; Karen M Kuntz; Robert L Kane; Beth A Virnig
Journal:  J Natl Cancer Inst       Date:  2012-03-22       Impact factor: 13.506

2.  [Prognostic factors in ductal carcinoma in situ].

Authors:  A Lebeau
Journal:  Pathologe       Date:  2006-09       Impact factor: 1.011

Review 3.  Current Therapeutic Approaches to DCIS.

Authors:  Kaleigh Doke; Shirley Butler; Melissa P Mitchell
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-09-29       Impact factor: 2.673

4.  Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions.

Authors:  Chieh-Yu Lin; Kelly Mooney; Winward Choy; Soo-Ryum Yang; Keegan Barry-Holson; Kathleen Horst; Irene Wapnir; Kimberly Allison
Journal:  Mod Pathol       Date:  2017-12-15       Impact factor: 7.842

Review 5.  Ductal Carcinoma In Situ: Treatment Update and Current Trends.

Authors:  Katrina B Mitchell; Henry Kuerer
Journal:  Curr Oncol Rep       Date:  2015-11       Impact factor: 5.075

Review 6.  Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ.

Authors:  Tatyana Shamliyan; Shi-Yi Wang; Beth A Virnig; Todd M Tuttle; Robert L Kane
Journal:  J Natl Cancer Inst Monogr       Date:  2010

Review 7.  The impact of surgery on ductal carcinoma in situ outcomes: the use of mastectomy.

Authors:  E Shelley Hwang
Journal:  J Natl Cancer Inst Monogr       Date:  2010

8.  Proteome-wide profiling of the MCF10AT breast cancer progression model.

Authors:  Lee Yee Choong; Simin Lim; Poh Kuan Chong; Chow Yin Wong; Nilesh Shah; Yoon Pin Lim
Journal:  PLoS One       Date:  2010-06-09       Impact factor: 3.240

9.  Investigational Paradigms in Downscoring and Upscoring DCIS: Surgical Management Review.

Authors:  P Orsaria; A V Granai; D Venditti; G Petrella; O Buonomo
Journal:  Int J Surg Oncol       Date:  2012-05-16

10.  Independent predictors of breast malignancy in screen-detected microcalcifications: biopsy results in 2545 cases.

Authors:  G Farshid; T Sullivan; P Downey; P G Gill; S Pieterse
Journal:  Br J Cancer       Date:  2011-11-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.